GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Research & Development

Instituto Rosenbusch (BUE:ROSE) Research & Development : ARS0 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Instituto Rosenbusch Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Instituto Rosenbusch's Research & Development for the three months ended in Sep. 2024 was ARS0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was ARS0 Mil.

Instituto Rosenbusch Research & Development Historical Data

The historical data trend for Instituto Rosenbusch's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instituto Rosenbusch Research & Development Chart

Instituto Rosenbusch Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Instituto Rosenbusch Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Instituto Rosenbusch Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch  (BUE:ROSE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Instituto Rosenbusch Research & Development Related Terms

Thank you for viewing the detailed overview of Instituto Rosenbusch's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Instituto Rosenbusch Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Research & Development
Comparable Companies
BSP:ARXD11 BSP:DMVF3 BSP:SNCI11 BSP:NUTR3 BSP:JOPA3 BSP:HUCG11 BSP:DTCY3 BSP:FATN11 BSP:DVFF11 BSP:BMIN3 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Website
https://www.rosenbusch.com
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.